A 104‐Week Real‐World Outcome of Bimekizumab Treatment for Psoriasis: Biologic‐Naïve Versus ‐Experienced Patients

Long‐term (2‐year) effectiveness of bimekizumab for psoriasis is unknown in real‐world practice. This study is aimed at evaluating 104‐week real‐world effectiveness of bimekizumab in patients with psoriasis, stratified by the presence or absence of prior biologic treatment. From May 2022 to May 2025, we prospectively assessed 66 Japanese patients With psoriasis who received bimekizumab 320 mg every 4 weeks (Q4W) until week 16, thereafter Q4W ( n = 28) or Q8W ( n = 38) assigned based on patients' preference. Both Q4W and Q8W bimekizumab regimens rapidly decreased the psoriasis area and severity index (PASI) to approximately 0 by week 16, which was sustained through week 104. The speed of achieving PASI 90, 100, or static physician's global assessment (sPGA) 0/1 was faster for biologic‐experienced patients compared to naïve ones in the Q4W regimen while faster for biologic‐naïve patients in the Q8W regimen. The above achievement rates in biologic‐naïve patients were maintained through week 104 while those in biologic‐experienced patients slightly reduced later than week 68 or 92 in the Q4W or Q8W regimen, respectively. Taken together, Q4W and Q8W treatment with bimekizumab rapidly improved symptoms of psoriasis, and the improvement was mostly maintained through week 104. The achievement rates of PASI 90, 100, or sPGA 0/1 were mostly sustained through week 104 in biologic‐naïve patients while slightly reduced in biologic‐experienced patients at later phases of treatment.